No regulatory body Health Canada, the FDA, the EMA, the TGA, or any equivalent has approved ipamorelin as a drug for human or veterinary use
Sermorelin is a Growth Hormone Releasing Hormone (GHRH) that stimulates directly binds to the pituitary gland to release growth hormone
Our mitochondriathe cells energy production centersare dependent on glutathione, which can cross mitochondrial membranes, minimize reactive oxygen species (ROS) buildup and hence maintain the redox balance inside cells
GHRH agonists have also been found to influence wound healing, activate immune cells, and impact the central nervous system
More significant changes including enhanced muscle mass, reduced body fat, and comprehensive body composition improvements typically become evident after three to six months of consistent therapy
Closed or near-closed epiphyses being a goal of approved use